

Quantitative COVID-19 (RBD) Antibody Testing Services

- Measure antibodies that bind the RBD of the virus - significantly associated with neutralization
- Reproducible quantitative numerical output: accurately track levels over time
- Validated performance for a variety of sample types, including at-home dried blood spots (DBS)
- High-throughput CLIA laboratory testing service, easy workflow and fast turnaround times

SARS-CoV-2 (RBD) IgG Antibody Test Performance

The sensitivity of the SARS-COV-2 (RBD) IgG Antibody test was assessed by analyzing blood samples from 69 individuals with prior SARS-CoV-2 infections confirmed by PCR. As shown in the table below, the Positive Percent Agreement (PPA) was 100% for all samples acquired ≥ 15 days post onset of symptoms. For samples acquired earlier (0-14 days), the PPA decreased to 50% reflecting variable seroconversion rates among individuals. For individuals sampled >112 days post symptoms onset, the mean index value was lower than that observed at earlier time points; however, all samples remained positive (index >1.0).

The specificity of the SARS-COV-2 (RBD) IgG Antibody test was assessed by analyzing blood samples acquired pre-pandemic. Several populations were assessed including adults covering a range of demographic categories, chronic conditions, exposure to common infectious diseases and vaccination history and children who had been hospitalized for a variety of conditions. The Negative Percent Agreement (NPA) was 98.9% or greater for all groups (99.4% overall). Specificity of the assay was further tested with samples with confirmed levels of antibodies to other infectious agents (e.g., HIV-1, HCV, CVM, etc.), which yielded negative results for all tested.

Positive Percent Agreement (PPA)

Days after Symptoms Onset	ProterixBio SARS-CoV-2 (RBD) IgG Antibody Test				
	Total	Mean Index*	Positive	Negative	PPA
0 - 14 days	6	2.1	3	3	50%
15 - 28 days	9	10.5	9	0	100%
29 - 56 days	33	13.5	33	0	100%
57 - 112 days	14	25.1	14	0	100%
113 - 165 days	7	9.9	7	0	100%

*Average of sample index values from different individuals

Negative Percent Agreement (NPA)

Pre-2019, U.S. Population Groups	ProterixBio SARS-CoV-2 (RBD) IgG Antibody Test			
	Total	Positive	Negative	NPA
Children (<18 yrs)	100	0	100	100%
Adults (18-80 yrs)	127	0	127	100%
Adults w/ chronic respiratory disease (50-80 yrs)	282	3	279	98.9%

Quantitative Performance

The assay output is a quantitative numerical Index that is the ratio of the antibody concentration of the sample to that of a controlled calibrator level. The test Index calibrates to the WHO First Standard 20/136 material linearly to within a few percent across the assay range. The table below illustrates excellent precision across the measurement range. Additionally, the assay recovers to within 10% of expected for a range of samples spiked with the Standard. Samples above the assay range are diluted to achieve a reportable result.

Precision

Sample I.D.	N	Mean Index	Within Run		Day to Day	
			SD	CV%	SD	CV%
Sample A	80	16.65	1.23	7.1	0.60	3.6
Sample B	80	6.80	0.52	7.3	0.50	7.4
Sample C	80	3.39	0.17	4.7	0.28	8.2
Sample D	80	1.66	0.11	7.1	0.28	16.7
Sample E	80	0.54*	0.05	11.3	0.10	17.8

*Measured level is below the pos/neg cut-off (Index = 1) but above LoQ for the assay


Linearity

Sample I.D.	Dilution	Observed Index	% CV	% Dev from Lin. Fit
Sample F (representative of multiple individual samples tested)	1	>ULIM		
	1:2	25.7	5.8	-5.9
	1:4	13.9	9.7	1.0
	1:8	6.7	6.9	-3.9
	1:16	3.5	3.0	-0.8
	1:32	1.9	5.3	2.3
	1:64	1.2	5.8	12.5

Neutralizing Activity

Seropositive samples (N=26), all >20 days post symptoms onset, were characterized with an independently validated neutralization assay, provided under CLIA, and the ProterixBio (RBD) SARS-CoV-2 IgG Antibody test.

The data are significantly associated with Spearman rank-order, correlation coefficient = 0.74 and p value < 0.001.




Dried Blood Spot / Finger Stick Performance

Dried blood spots (DBS) from finger sticks are compared to venous EDTA plasma (N=37).

Deming regression of ProterixBio SARS-CoV-2 (RBD) IgG Antibody test index values measured in both samples yielded a fit with slope = 1.06, $p < 1e-30$, and a correlation coefficient = 0.99.

These data demonstrate the equivalence of the quantitative test performance in the different sample types.



References

- CDC Overview of Testing for SARS-CoV-2 (COVID-19), <https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html>, Aug 2020.
- FDA Policy for COVID-19 Tests During the Public Health Emergency (Revised), <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised>, Aug 2020
- Krammer, F. and Simon, V., Serology assays to manage COVID-19, Science, 15May, 2020.
- Long et al, Antibody responses to SARS-CoV-2 in COVID-19 patients: perspective application of serological tests in clinical practice, medRxiv, 20March, 2020.
- Okba et al, Severe Acute Respiratory Syndrome Coronavirus 2–Specific Antibody Responses in Coronavirus Disease Patients Emerg Infect Dis, 2020; 26(7).
- Atjeo et al, Distinct early serological signatures track with SARS-CoV-2 survival, Immunity 53, 1-9, 2020.
- Vandergaast et al, Development and validation of a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2, BioRxiv, 27May, 2020.
- Premkumar et al, The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of the antibodies in the SARS-CoV-2 patients, Science Immunology, 11June 2020.
- Seow et al, Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection, medRxiv, 11July, 2020
- Gudbjartsson et al., Humoral Immune Response to SARS-CoV-2 in Iceland, NEJM, 1Sept 2020.